FindTrial
Sign In

Semaglutide (Wegovy) weekly injection

DRUG5 trials

Sponsors

Vivani Medical, Inc, Veru Inc., University of Health Sciences, Algeria, University of Massachusetts, Worcester, The Methodist Hospital Research Institute

Conditions

Endometrial Atypical HyperplasiaEndometrial Atypical Hyperplasia/Endometrioid Intraepithelial NeoplasiaEndometrial CancerEndometrial Cancer Stage IFertility-Sparing Treatment (FST)Gestational Diabetes Mellitus (GDM)HOMA-IRMetabolic Syndrome

Phase 1

Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant
Not yet recruitingNCT07430059
Vivani Medical, IncObesity & Overweight
Start: 2026-07-01End: 2027-01-01Target: 20Updated: 2026-06-30

Phase 2

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
Active, not recruitingNCT07446998
Veru Inc.HOMA-IR, Mobility Disability, Obesity & Overweight
Start: 2026-03-26End: 2027-12-01Updated: 2026-09-04
Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes
Not yet recruitingNCT07797036
University of Massachusetts, WorcesterGestational Diabetes Mellitus (GDM), Metabolic Syndrome
Start: 2027-09-01End: 2030-12-31Target: 226Updated: 2026-09-01
Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer
Not yet recruitingNCT07820358
The Methodist Hospital Research InstituteEndometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Cancer +3
Start: 2027-01-01End: 2031-12-31Target: 48Updated: 2026-09-15

Unknown Phase

OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme
RecruitingNCT07779343
University of Health Sciences, AlgeriaObesity Adult Onset, Obesity and Cardiovascular Risk, Obesity Difficult Airway Airway Management +1
Start: 2026-01-22End: 2028-01-23Target: 300Updated: 2026-08-21